In 2026, pharma and biotech are evolving at unprecedented speed. AI-driven drug discovery, digital transformation, personalized medicine, and tightening market access pressures are reshaping how decisions are made. Staying informed is no longer optional—it’s a strategic necessity.

This curated list features the Top 10 Pharma News Websites that ...

In 2026, raising capital in life sciences is no longer about access—it is about proof. The traditional reliance on large IPOs and venture rounds has shifted toward a hybrid model combining private funding, strategic partnerships, milestone-based financing, and selective public market access.

The direct answer is clear: capital in 2026 flows to ...

Kailera Therapeutics has provided additional details regarding its planned initial public offering, aiming to raise up to $528.5 million to support the continued clinical development of its obesity-focused drug pipeline. The company intends to list its shares ...

Artificial intelligence startup Keebler Health has secured $16 million in a Series A financing round aimed at supporting the development of its infrastructure for value-based care. The round was led by Flare Capital Partners, with participation from Sands Capital, Tau Ventures, and several existing investors, including Freestyle Capital, Underdog Labs, and MBX Capital. Additi...

A new biotechnology company, Beeline Medicines, has emerged from stealth following its creation by Bristol Myers Squibb in partnership with Bain Capital. The initiative was first announced in July 2025 and involved Bristol Myers Squibb contributing an initial pip...